Welcome to our dedicated page for BPTSY news (Ticker: BPTSY), a resource for investors and traders seeking the latest updates and insights on BPTSY stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BPTSY's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BPTSY's position in the market.
Biophytis SA (OTC Pink: BPTSY) has entered exclusive negotiations with a leading Chinese pharmaceutical company to establish a licensing agreement for BIO101 (20-Hydroxyecdysone). The agreement aims to co-develop and commercialize BIO101 in China for treating viral respiratory infections, sarcopenia, and obesity.
The potential partner is part of a major Chinese group with expertise in innovative technologies and access to China's rapidly growing market. This development follows Biophytis' partnership strategy, building on their previous agreement with Blanver for the LATAM region. The Chinese market represents a significant opportunity, with 70 million obesity patients and 30 million sarcopenia patients. China is currently the second-largest pharmaceutical market globally, valued at $190 billion.
